How can germline mutations distinguish risk for lethal and indolent prostate cancer?

Rong Na, MD, from the Huashan Hospital, Fudan University, Shanghai, China discusses germline mutations in prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He introduces a study whose aim was to evaluate the association between germline mutations in DNA repair genes and the risk of prostate cancer, which evaluated the rate of carriers in lethal and indolent prostate cancer patients, as well as survival time. Dr Rong Na also discusses the next steps in this study.
Share this video